Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

Cited by (772)

Items 501–600 of 772

1. Comparison of Efficacy of Intensive versus Mild Pitavastatin Therapy on Lipid and Inflammation Biomarkers in Hypertensive Patients with Dyslipidemia
   Tomohiro Yamasaki, Yoshio Iwashima, Subrina Jesmin, Yuko Ohta, Hiroshi Kusunoki, Shin-ichiro Hayashi, Takeshi Horio, Yuhei Kawano · 2014 · PLoS ONE
2. SEARCHing for JUPITER: starry-eyed optimism is not warranted
   Anthony S. Wierzbicki · 2009 · International Journal of Clinical Practice
3. HDL – a difficult friend
   Arnold von Eckardstein · 2008 · Drug Discovery Today Disease Mechanisms
4. Pleiotropic Effects of Statins and Beyond
   Peter J. Lansberg · 2008 · Cardiology
5. Diabetic Dyslipidemia
   Francesco Paneni, Francesco Cosentino · 2015 · Springer eBooks
6. METEOR: aiming at the stars for asymptomatic carotid artery atherosclerosis?*
   Kosmas I. Paraskevas, Anthony S. Wierzbicki, Dimitri P. Mikhailidis · 2007 · International Journal of Clinical Practice
7. Newer, lower, better? Lipid drugs and cardiovascular disease - the continuing story
   Anthony S. Wierzbicki · 2007 · International Journal of Clinical Practice
8. THE EFFECT OF EVOLOCUMAB ALONE AND IN COMBINATION WITH ATORVASTATIN ON LIPID PROFILE
   Ali Saud, Nabeel A. J. Ali, Fadhil Y. Gali, Najah Raiesh Hadi · 2021 · Wiadomości Lekarskie
9. Optimization of the MACE endpoint composition to increase power in studies of lipid-lowering therapies—a model-based meta-analysis
   Alina Volkova, Boris Shulgin, Gabriel Helmlinger, Kirill V. Peskov, Victor V. Sokolov · 2024 · Frontiers in Cardiovascular Medicine
10. Managing acute coronary syndromes: Decades of progress
    Abraham Michael Lincoff · 2014 · Cleveland Clinic Journal of Medicine
11. Lipids, statins, and clinical outcomes in heart failure: rethinking the data
    Muthiah Vaduganathan, Stephen John Greene, Andrew P. Ambrosy, Mihai Gheorghiade · 2014 · Heart Failure Reviews
12. Optimización fármaco-económica del tratamiento de la hipercolesterolemia con estatinas
    Antonio Ruiz García, Francisco Javier Gordillo López, Ezequiel Arranz Martínez, Juan Carlos Hermosa Hernán · 2010 · Medicina Clínica
13. New cholesterol guidelines and the secondary prevention of cardiovascular disease — A commentary on epistemic aspects
    José Pedro L. Nunes · 2014 · Preventive Medicine
14. Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
    Shaimaa Ahmed Mostafa, Kh. Elrabat, Mohamed Mahrous, Manar Ahmed Kamal · 2018 · Rational Pharmacotherapy in Cardiology
15. The Clinical Aspects of Saroglitazar and its Side Effects
    Vadlamudi Naga Ratna Sai, Sreenivas Pasula, Sheelam Sumathi, Mondra Sreekanth, A. Srinivas Rao, Beda Durga Prasad · 2020 · Journal of Drug Delivery and Therapeutics
16. Atingimento das Metas de Colesterol LDL em Pacientes com Histórico de Infarto Agudo do Miocárdio: Estudo Transversal do Mundo Real
    D Gomes, Mariana Sousa Paiva, Pedro Freitas, Francisco Albuquerque, Maria Rita Lima, Rita Reis Santos, J Presume, Marisa Trabulo, Carlos Aguíar, Jorge Ferreira et al. · 2024 · Arquivos Brasileiros de Cardiologia
17. Cardiovascular Risk Management in Clinical Practice
    Massimo Volpe, Leif Erhardt, Bryan Williams · 2008 · High Blood Pressure & Cardiovascular Prevention
18. Mechanism of Statin-Induced Myopathy Investigated Using Microarray Technology
    Takahide Kohro, Tsutomu Yamazaki · 2009 · Journal of Atherosclerosis and Thrombosis
19. Proactive Multifactorial Intervention Strategy Reduces the Risk of Cardiovascular Disease Estimated with Region-Specific Risk Assessment Models in Pacific Asian Patients Participating in the CRUCIAL Trial
    Eun Joo Cho, Jae Hyung Kim, Santosh Sutradhar, Carla Yunis, Mogens Westergaard, CRUCIAL Trial Investigators · 2013 · Journal of Korean Medical Science
20. 2008 White Paper for Implementing Strategies and Interventions for Cardiovascular Prevention in Italy
    Massimo Volpe · 2008 · High Blood Pressure & Cardiovascular Prevention
21. Utility of Early High Dose Statins in Acute Coronary Syndrome
    Philip J. Dougherty, Rohit Romesh Arora · 2012 · American Journal of Therapeutics
22. A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals
    Harold Edward Bays · 2015 · Journal of clinical lipidology
23. Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia
    Vineet Bhatia, Parneesh Arora, Gagandeep Kaur, Upendera Kaul · 2017 · Heart Research - Open Journal
24. Early treatment with high-potency statins in patients with acute coronary syndrome—an example of personalized medicine
    Emanuel Harari, Alon Eisen · 2018 · Journal of Thoracic Disease
25. The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease
    Pavla Vorlíčková, Otto Mayer, Jan Bruthans, Jitka Seidlerová, Július Gelžinský, Markéta Mateřánková, Martina Cvíčela, Renata Cífková, Jan Filipovský · 2018 · Cor et Vasa
26. Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study
    Yong Hoon Kim, Ae‐Young Her, Myung Ho Jeong, Byeong‐Keuk Kim, Sung‐Jin Hong, Seunghwan Kim, Chul‐Min Ahn, Jung‐Sun Kim, Young‐Guk Ko, Donghoon Choi et al. · 2021 · BMC Cardiovascular Disorders
27. Intensity of statin therapy and primary prevention of cardiovascular in Korean patients with dyslipidemia
    Sun Ok Song, Min Jin Kang, Sunghwan Suh · 2024 · Medicine
28. Impact of Intensive Blood Pressure Control Versus Standard Control on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Ufn Rizwanullah, Allenki Vineesh, Fardin Akbar Hyderi, Shivani Shah, Mihika Sawale, Tahera Ahmadi, Pavan Kumar Makam Surendraiah, Sneha Kanduri Hanumantharayudu, Fazeel Hussain, Chet Raj Awasthi et al. · 2025 · Cureus
29. Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis
    Huaidong Wang, Xiaotian Zhang, Yuanxiang Bai, Zipeng Duan, Yan Lin, Guoqing Wang, Fan Li · 2015 · Journal of Clinical Bioinformatics
30. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry
    Peter Paul Toth · 2011 · Yearbook of Endocrinology
31. Statins: targeting cardiovascular disease
    Farouk Mamdoo, Frederick Johan Raal · 2017 · SA Heart
32. Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists
    Pishoy Gouda, Robert C. Welsh, Michelle Padarath, Jean C. Grégoire, Robert Alexander Hegele, Milan Gupta · 2020 · CJC Open
33. Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin
    Andrey V. Susekov · 2023 · Kardiologiia
34. Novel bioactive lipids enhanced HDL-mediated cholesterol efflux from macrophages through the ABCA1 receptor pathway
    Ali Khattib, Manar Shmet, Rasha Ashkar, Tony Hayek, Soliman Khatib · 2023 · Chemistry and Physics of Lipids
35. Trials in “True” Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
    José Pablo Werba, Lorenzo Vigo, Fabrizio Veglia, Giancarlo Marenzi, Elena Tremoli, Damiano Baldassarre · 2019 · Clinical Pharmacology & Therapeutics
36. Uso adecuado de las estatinas de alta intensidad
    Masson, Walter · 2019 · Revista Uruguaya de Cardiología
37. The combined antihypertensive and antilipid treatment as a polypill therapeutic preventive strategy is a mean column of hypertensive patients with high cardiovascular risk
    Ede Kékes · 2008 · Orvosi Hetilap
38. Lipid control in patients with coronary heart disease treated in primary care or cardiology clinics
    David Pereg, Avishay Elis, Yoram Neuman, Morris Mosseri, Avi Leader, David Segev, Martine Granek-Catarivas, Michael Lishner, Doron Hermoni · 2013 · Journal of clinical lipidology
39. Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk
    Binh An P. Phan, Peter Paul Toth · 2013 · Clinical Lipidology
40. Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review
    JoAnne Micale Foody, Naderi · 2012 · International Journal of Nephrology and Renovascular Disease
41. Effectiveness of statin therapy for elderly acute myocardial infarction patients with normal levels of low-density lipoprotein cholesterol
    Futoshi Yamanaka, Myung Ho Jeong, Shigeru Saito, Youngkeun Ahn, Shung Chull Chae, Seung‐Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae et al. · 2012 · International Journal of Cardiology
42. Cardiovascular effects of testosterone
    Graham Jackson · 2008 · Current Sexual Health Reports
43. IMPACT OF DIFFERENT STARTING DOSES OF ATORVASTATIN ON REACHING TARGET LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND HEALTH RELATED QUALITY OF LIFE IN DYSLIPIDEMIC PATIENTS
    Ghia Cj, Panda Sk, Khobragade Lr, Rajesh Kumar Jha · 2013
44. Management of acute coronary syndrome in special subgroups: female, older, diabetic and Indigenous patients
    B. McQuillan, Peter Lindsay Thompson · 2014 · The Medical Journal of Australia
45. Actualización en cardiopatía isquémica 2006
    Xavier García–Moll, Alfredo Bardajı́, Joaquín J. Alonso, Héctor Bueno · 2007 · Revista Española de Cardiología
46. Lipid management after acute coronary syndrome
    Gregory G. Schwartz · 2008 · Current Opinion in Internal Medicine
47. Lipid-Modifying and Antiatherosclerotic Drugs
    Antonio M. Gotto, Lionel Henry Opie · 2009 · Elsevier eBooks
48. Hyperlipidemia Management for Primary Care
    Brian V Reamy · 2008 · Springer eBooks
49. Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy
    И. А. Алексеева, Колмакова Татьяна Евгеньевна, Ежов Марат Владиславович · 2019 · Meditsinskiy sovet = Medical Council
50. Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
    Daisaku Masuda, Arihiro Kiyosue, Atsushi Hirayama, Junichiro Shimauchi, J. Antonio G. López, Kazumasa Miyawaki, Shizuya Yamashita · 2020 · Journal of Atherosclerosis and Thrombosis
51. Evaluation of academic detailing visits on GP knowledge and practice for statin use and management
    Isla M. Hains, Natalie Raffoul, Jeannie Yoo · 2020 · Australian Journal of Primary Health
52. New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins
    KAMIR-NIH Investigators, Jah Yeon Choi, Cheol Ung Choi, Byoung Geol Choi, Yoonjee Park, Dong Oh Kang, Won Young Jang, Woohyeun Kim, Jin Oh Na, Jin Won Kim et al. · 2021 · BMC Pharmacology and Toxicology
53. Therapy and clinical trials
    Ganesh P. Devendra, Richard A. Krasuski · 2010 · Current Opinion in Lipidology
54. Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear
    Jennifer G. Robinson, Helmut G. Schrott · 2007 · Cardiovascular Drugs and Therapy
55. Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
    Jane Armitage · 2008 · Heart
56. How a Meta‐Analysis Works
    2021
57. Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    2025 · JMA Journal
58. Intensive lipid-lowering strategies and major cardiovascular events in patients aged ≥65 years: A meta-analysis of randomized trial subgroups
    Armando Oterino, Rosa Fernández Olmo, Miriam Martín Toro, Alberto Cordero · 2026 · Atherosclerosis
59. Danshen decoction stabilizes vulnerable atherosclerotic plaques by maturating intraplaque neovessels via the Piezo1/yes-associated protein/angiopoietin-1 pathway
    Xiran Guo, Peina Meng, Lei Zhang, Muhan Zhou, Li Y, Qian Liu, Yuan Fang, Xiaojin Xu, K Pei · 2026 · Journal of Ethnopharmacology
60. Challenges to implementing expanded team models: lessons from a centralised nurse-led cholesterol-lowering programme
    Emily K. Kadehjian, Louise I. Schneider, Jeffrey O. Greenberg, Jessica C. Dudley, Allen B. Kachalia · 2013 · BMJ Quality & Safety
61. the American Heart Association and American College of Cardiology Foundation Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With
    Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager · 2014
62. Analysis of secondary prevention measures implemented in patients with a history of acute coronary syndrome
    Jorge Enrique Machado‐Alba, Manuel Enrique Machado‐Duque, Diego Alejandro Medina-Morales, Claudia Giraldo‐Giraldo · 2018 · Revista Colombiana de Cardiología
63. The Presence of Residual Vascular and Adipose Tissue Inflammation on 18F-FDG PET in Patients with Chronic Coronary Artery Disease
    Sini Toivonen, Miia L. Lehtinen, Peter M. Raivio, Juha P. Sinisalo, Antti Loimaala, Valtteri Uusitalo · 2022 · Nuclear Medicine and Molecular Imaging
64. Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
    Jieun Lee, Jah Yeon Choi, Byoung Geol Choi, You-Jung Choi, Soohyung Park, Dong Oh Kang, Eun Jin Park, Ji Bak Kim, Seung‐Young Roh, Jin Oh Na et al. · 2024 · Scientific Reports
65. The Efficacy of Intensive Statin Therapy in Acute Ischemic Stroke Following Intravenous Thrombolysis: The CASE II Study
    Fujian Chen, Huan Zhou, Tingxia Zhang, Liang Wang, Hongfang Chen, Jin Hu, Guomin Xie, Shenqiang Yan, Min Lou, CASE‐II Investigators · 2025 · CNS Neuroscience & Therapeutics
66. Lipid-lowering therapy in patients with coronary artery disease in primary care practices: what has changed over 7 years?
    Sergey Kensarinovich Zyryanov, Sergey B. Fitilev, Alexander V. Vozzhaev, Шкребнёва Ирина Ивановна, Dmitry A. Klyuev, L. N. Stepanyan, A. A. Danilova, A. T. Tsai, Nikolay N. Landyshev, Ya. G. Voronko · 2020 · CARDIOVASCULAR THERAPY AND PREVENTION
67. Management Options in Chronic Stable Angina Pectoris: Focus on Ranolazine
    David S. Vadnais, NANETTE KASS WENGER · 2009 · Clinical Medicine Therapeutics
68. ¿Se están alcanzando las metas en el perfil lipídico de personas con enfermedad coronaria previa?
    Alonso Merchán, Claudia Jaramillo, Fernán del C. Mendoza, Juan Fernando Agudelo · 2011 · Revista Colombiana de Cardiología
69. Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients
    Joseph P. Vande Griend, Joseph J. Saseen · 2009 · Journal of clinical lipidology
70. The Efficacy of Statin Therapy in Patients with Acute Coronary Syndromes and Concomitant Carotid Disease
    Roman Komorovsky, Alessandro Desideri, Sebastian Coscarelli, Diego Tonello, Adriana Visonà, Leopoldo Celegon · 2009 · Clinical Cardiology
71. Modern statin therapy in clinical practice: The lower the better
    Edita Stokić · 2013 · Srpski arhiv za celokupno lekarstvo
72. Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (the JUPITER trial)
    Nathan D. Wong · 2009 · Current Cardiovascular Risk Reports
73. The Need for Increased Utilization of Statins After Occlusive Stroke
    Patricia R. Hebert, Denis A. Evans, Wendy R. Schneider, Enrique Rodriguez‐Paz, Charles H. Hennekens · 2010 · Journal of Cardiovascular Pharmacology and Therapeutics
74. Lipid goals in metabolic syndrome and diabetes
    Helen Martina Colhoun · 2007 · Current Atherosclerosis Reports
75. Benefits of lipid regulation in acute coronary syndrome
    Chris J. Packard, Alexandra Parade · 2010
76. Dislipidemia e statine: dalle linee guida alla pratica clinica.Una rassegna aggiornata della letteratura
    Tiziano Angelo Lucchi, Carlo Vergani · 2014 · Giornale italiano di cardiologia
77. the Society for Cardiovascular Angiography and Interventions Foundation/American Heart Association Task Force on Practice Guidelines and Executive Summary : A Report of the American College of Cardiology 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:
    Issam D. Moussa, Brahmajee K. Nallamothu, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton et al. · 2011
78. Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia
    P. Toth, D. Nikolić, Manfredi Rizz, J. Rysz, M. Banach · 2015 · Springer eBooks
79. Dyslipidemia in Racial/Ethnic Groups
    Luther T. Clark, Syca Shaheen · 2009 · Humana Press eBooks
80. The challenges of proprotein convertase subtilisin–kexin-9 inhibitors for lipid guidelines and models of care
    Anthony S. Wierzbicki · 2017 · Current Opinion in Lipidology
81. Serial assessment of endothelial function 1, 6, and 12 months after ST-elevation myocardial infarction
    Jasveen J. Kandhai-Ragunath, Carine J.M. Doggen, Liefke C. van der Heijden, Marlies M. Kok, Paolo Zocca, Bjorn de Wagenaar, Cees Doelman, Harald Thune Jorstad, Ron J.G. Peters, Clemens von Birgelen · 2018 · Heart and Vessels
82. Comparison of Adverse Events between High-intensity and Moderate- to Low-intensity Statin Group
    Sera Lee, Miyoung Ock, Hyunah Kim · 2018 · Korean Journal of Clinical Pharmacy
83. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults
    William E. Braun · 2008 · Elsevier eBooks
84. Influence of Low Carbohydrate High Fat Ketogenic Diets on Renal and Liver Parameters
    Bibiana Omozee Eiya, R.O. Aikpitanyi-Iduitua · 2020 · International Journal of Chemistry
85. Assessing the effect of socioeconomic factors on prevalence of dyslipidemia among iranian adult population; district level analysis from 2016 STEPS national study using small area estimation
    Hamidreza Soleimani, Erfan Ghasemi, Sahar Saeedi Moghaddam, Sina Azadnajafabad, Negar Rezaei, Masoud Masinaei, Shohreh Naderimagham, Nazila Rezaei, Mohammad‐Reza Malekpour, Mohammad Keykhaei et al. · 2022 · Journal of Diabetes & Metabolic Disorders
86. Logro de metas de prevención secundaria, prescripción farmacológica y eventos cardiovasculares mayores en pacientes con enfermedad coronaria
    Víctor Neira, Marcelo Potthoff, Luis Quiñiñir S, Gabriel López R, Benjamín Stockins F, Carlos Castillo B, Fernando Tomas Lanas · 2013 · Revista médica de Chile
87. ENHANCE: food for the ostriches
    Graham Jackson · 2008 · International Journal of Clinical Practice
88. Stable and also unstable coronary disease - COURAGE and the importance of optimal medical therapy
    Graham Jackson · 2007 · International Journal of Clinical Practice
89. Time for new low density lipoprotein cholesterol (LDL-C) targets?
    Stella Styliani Daskalopoulou, Dimitri P. Mikhailidis · 2017 · Expert Opinion on Pharmacotherapy
90. Quantitation of anacetrapib in human and animal adipose by liquid chromatography with mass spectrometric detection
    Wei Fang, C.M. Chavez-Eng, Ryan Lutz, Hankun Li, Jessica Schlegel, Brad A. Roadcap, James E. Schiller, Eric Woolf · 2024 · Bioanalysis
91. Current Status of Lipid Management and Subsequent Cardiovascular Events After Acute Coronary Syndrome in Korea: Real-World Findings From Observational and Survey Studies
    Jong‐Young Lee, Chang‐Hwan Yoon, Jin‐Yong Hwang, Jung‐Sun Kim, Kwang‐Soo Cha, Doo‐Il Kim, Jin Bae Lee, Seung‐Ho Hur, Jung‐Hee Lee, Kiyuk Chang et al. · 2025 · Journal of Cardiovascular Intervention
92. 44 Drugs that affect lipid metabolism
    Ivar Aursnes · 2007 · Side effects of drugs annual
93. The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe
    Finn O. Akerström, Luis Rodrı́guez Padial · 2011 · Clinical Investigation
94. Modern cardiovascular risk management in clinical practice
    Massimo Volpe, Camilla Calvieri, Alessandro Alonzo · 2009 · Hipertensión y Riesgo Vascular
95. Global cardiovascular risk: The benefits of a precocious, aggressive treatment strategy
    Claudio Bilato, Sabino Iliceto · 2007 · International Congress Series
96. Effects of Achieving LDL-Cholesterol Levels <70 mg/dL With Simvastatin or Atorvastatin on Steroidogenesis in High-Risk Diabetic Patients
    Zehra Berberoğlu, Nilgun Demirag Guvener, Mehmet Aşık, Ayşe Canan Yazıcı, Nilüfer Bayraktar · 2009 · The Endocrinologist
97. Prospective Study to Evaluate the Efficacy and Safety of Pitavastatin in Patients with Risk Factor of Cardiovascular Disease(PEACE Study)
    Cheol‐Ho Kim, Kwang‐Il Kim, Jae-Hyung Kim, Jae‐Eun Jun, Jong-Hwa Bae, Jae Wook Lee, Kyung‐Hoon Choe, Soon‐Pyo Hong, Bang-Hun Lee · 2007 · Korean Circulation Journal
98. Reaching Target Lipid Levels in Patients at High Risk of Cardiovascular Event: The Experience of a Canadian Tertiary Care Lipid Clinic
    Jennifer A. Klinke, Filip Málek, Min Gao, Daniel Thomas Holmes, Jiri J Frohlich · 2007 · Central European Journal of Public Health
99. Coronary Artery Disease and Cardiomyopathy
    Richard B. Devereux · 2009 · Springer eBooks
100. Intensive Statin Therapy in Coronary Artery Disease: Is Lower Cholesterol Better and Safe?
     Sreenivasa Rao Kondapally Seshasai, Kausik Kumar Ray · 2009 · Future Cardiology